BACKGROUND: This study aimed to quantify the direct medical cost of treating inflammatory bowel disease (IBD) in Manitoba in 2005/2006. METHODS: In all, 7375 individuals with IBD recorded in the University of Manitoba IBD Epidemiology Database were matched on age, gender, and geography to up to 10 non-IBD controls. Data for cases and controls were extracted from Manitoba Health databases in fiscal 2005/2006 for pharmaceutical, physician claims, and hospital abstracts. The mean and median expenditure were computed for the annual cost of pharmaceuticals, hospitalizations (day surgery and inpatient), and physician office visits. We assessed costs based on age, gender, type of IBD, disease duration, and level of care provided. RESULTS: In 2005/2006 the mean direct cost of an IBD case was $3896 (standard error [SE] = $90) which was twice that of controls (P < 0.05). Crohn's disease (CD; n = 3735) was significantly more costly on average than ulcerative colitis (UC; n = 3640) ($4232; SE = $137 and $3552; SE = $117, respectively, P < 0.001). The most costly cases included those within 1 year of diagnosis ($6611; SE = $593), those hospitalized overnight (15%) ($13,495, SE = $416; max = $130,332), those who had a surgical stay (2% of IBD cases) ($18,749, range = $13,413-$125,912), and those using infliximab (0.7%) ($31,440, SE = $2311; max = $96,328). For individuals using infliximab their direct annual average healthcare cost was $9683 (SE = $1745, Max = $55,208) prior to using infliximab. CONCLUSIONS: In Manitoba the direct average annual healthcare cost of CD is greater than UC and that of a patient using infliximab tends to be greater than one incurring a surgical stay.
BACKGROUND: This study aimed to quantify the direct medical cost of treating inflammatory bowel disease (IBD) in Manitoba in 2005/2006. METHODS: In all, 7375 individuals with IBD recorded in the University of Manitoba IBD Epidemiology Database were matched on age, gender, and geography to up to 10 non-IBD controls. Data for cases and controls were extracted from Manitoba Health databases in fiscal 2005/2006 for pharmaceutical, physician claims, and hospital abstracts. The mean and median expenditure were computed for the annual cost of pharmaceuticals, hospitalizations (day surgery and inpatient), and physician office visits. We assessed costs based on age, gender, type of IBD, disease duration, and level of care provided. RESULTS: In 2005/2006 the mean direct cost of an IBD case was $3896 (standard error [SE] = $90) which was twice that of controls (P < 0.05). Crohn's disease (CD; n = 3735) was significantly more costly on average than ulcerative colitis (UC; n = 3640) ($4232; SE = $137 and $3552; SE = $117, respectively, P < 0.001). The most costly cases included those within 1 year of diagnosis ($6611; SE = $593), those hospitalized overnight (15%) ($13,495, SE = $416; max = $130,332), those who had a surgical stay (2% of IBD cases) ($18,749, range = $13,413-$125,912), and those using infliximab (0.7%) ($31,440, SE = $2311; max = $96,328). For individuals using infliximab their direct annual average healthcare cost was $9683 (SE = $1745, Max = $55,208) prior to using infliximab. CONCLUSIONS: In Manitoba the direct average annual healthcare cost of CD is greater than UC and that of a patient using infliximab tends to be greater than one incurring a surgical stay.
Authors: Stephanie Coward; Steven J Heitman; Fiona Clement; James Hubbard; Marie-Claude Proulx; Scott Zimmer; Remo Panaccione; Cynthia Seow; Yvette Leung; Indraneel Datta; Subrata Ghosh; Robert P Myers; Mark Swain; Gilaad G Kaplan Journal: Can J Gastroenterol Hepatol Date: 2015-06-16
Authors: Stephanie Coward; Steven J Heitman; Fiona Clement; Maria Negron; Remo Panaccione; Subrata Ghosh; Herman W Barkema; Cynthia Seow; Yvette P Y Leung; Gilaad G Kaplan Journal: Am J Gastroenterol Date: 2014-10-28 Impact factor: 10.864
Authors: Angela Rocchi; Eric I Benchimol; Charles N Bernstein; Alain Bitton; Brian Feagan; Remo Panaccione; Kevin W Glasgow; Aida Fernandes; Subrata Ghosh Journal: Can J Gastroenterol Date: 2012-11 Impact factor: 3.522
Authors: Phillip Gu; Anshika Kapur; Dalin Li; Talin Haritunians; Eric Vasiliauskas; David Q Shih; Stephan R Targan; Brennan Mr Spiegel; Dermot Pb Mcgovern; Jeanne T Black; Gil Y Melmed Journal: J Dig Dis Date: 2018-01 Impact factor: 2.325
Authors: Rachel L Randell; Millie D Long; Christopher F Martin; Robert S Sandler; Wenli Chen; Kristen Anton; Michael D Kappelman Journal: Inflamm Bowel Dis Date: 2013-06 Impact factor: 5.325
Authors: Charles N Bernstein; Allan Garland; Christine A Peschken; Carol A Hitchon; Hui Chen; Randy Fransoo; Ruth Ann Marrie Journal: Inflamm Bowel Dis Date: 2015-06 Impact factor: 5.325